NCT07453446 is a Phase 1 clinical trial of CD30 CAR-T Cells in Relapsed or Refractory Lymphoma, sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.

Who is sponsoring NCT07453446?

NCT07453446 is sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.

What drugs are being tested in NCT07453446?

Interventions in NCT07453446: CD30 CAR-T Cells.

What condition does NCT07453446 study?

NCT07453446 studies Relapsed or Refractory Lymphoma.

Is NCT07453446 still recruiting?

NCT07453446 is currently recruiting now. Last updated 6 March 2026.

Last reviewed 2026-03-06 · How we verify

NCT07453446

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Recruiting now Phase 1 Last updated 6 March 2026

What this trial tests

Phase 1 trial testing CD30 CAR-T Cells in Relapsed or Refractory Lymphoma in 18 participants. Currently enrolling.

Timeline

4 March 2025

Primary endpoint
31 March 2027

31 March 2029

Quick facts

Lead sponsor	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	4 March 2025
Primary completion	31 March 2027
Estimated completion	31 March 2029
Sites	1 location across China

Drugs / interventions tested

CD30 CAR-T Cells — full drug profile →

Conditions studied

Relapsed or Refractory Lymphoma — all drugs for Relapsed or Refractory Lymphoma →

Sponsor

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd — full company profile →

Who can join

Adults 18 to 70, any sex, with Relapsed or Refractory Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label study conducted in subjects with relapsed or refractory CD30-positive lymphoma, with priority given to Hodgkin lymphoma and anaplastic large cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd trials

Trials by the same sponsor.

NCT07036250 — Clinical Study of U32 in Patients With Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
NCT07093073 — Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma · Phase 1 · recruiting
NCT07093086 — Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma · Phase 1 · recruiting
NCT06614686 — U87 CAR-T in Patients With Advanced Head and Neck Tumors · Phase 1 · recruiting
NCT05768529 — Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07453446 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Last refreshed: 6 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07453446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing